

Summary of Outpatient COVID-19 Treatment Options for Adult Patients (18+)
Does not include pre- or post-exposure prophylaxis

Population	Preferred	Alternatives	Contraindicated
No high-risk criteria ¹	Supportive care		
1+ high-risk criteria ¹	Paxlovid ²	2 nd line: Remdesivir ³ 3 rd line: Bebtelovimab ⁴ 4 th line: Molnupiravir ⁵	
Pregnant	Remdesivir ³	2 nd line: Bebtelovimab ⁴ 3 rd line: Paxlovid ² if benefit outweighs risk	Molnupiravir ⁵
ESRD with eGFR < 30 mL/min or Hemodialysis	Bebtelovimab ⁴	2 nd line: Remdesivir ³ 3 rd line: Molnupiravir ⁵	Paxlovid
Hepatic impairment (Child-Pugh Class C)	Bebtelovimab ⁴	2 nd line: Molnupiravir ⁵	Remdesivir Paxlovid
Transplant on immunosuppression	Remdesivir ³	2 nd line: Bebtelovimab ⁴ 3 rd line: Paxlovid ² with appropriate management of DDI with immunosuppressives 4 th line: Molnupiravir ⁵	

DDI = drug-drug interaction

¹**High-risk criteria:** Age 65+, BMI 25+, Pregnancy, CKD, Diabetes, Immunosuppressive disease/treatment, cardiovascular disease (including congenital heart disease), hypertension, chronic lung disease, sickle cell disease, neurodevelopmental disorder, medical-related technological dependence.

²**Nirmatrelvir/ritonavir (Paxlovid):** within 5 days of symptom onset; potential for clinically significant drug-drug interactions; renal dose adjustment required for eGFR 30-60 mL/min; although there is no human data, "[SMFM](#) supports the use of Paxlovid for treatment of pregnant patients with COVID-19 who meet clinical qualifications. Any therapy that would otherwise be given should not be withheld specifically due to pregnancy or lactation."

³**Remdesivir:** Within 7 days of symptom onset in unvaccinated or immunocompromised patients; 200 mg x1 on day 1, then 100 mg daily on days 2 and 3

⁴**Bebtelovimab:** Within 7 days of symptom onset

⁵**Molnupiravir:** within 5 days of symptom onset; embryo-fetal toxicity, bone and cartilage toxicity

More resources:

- <https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/>
- [Statement on Bebtelovimab | COVID-19 Treatment Guidelines \(nih.gov\)](#)
- [Adult or pediatric \(age 12 and older and weight 40kg or greater\) with mild to moderate COVID-19 & high risk for progression to severe disease \(phe.gov\)](#)
- [AST Statement on Oral Antiviral Therapy for COVID Jan 4 \(2\).pdf \(myast.org\)](#)



How to access oral antivirals

<https://healthdata.gov/Health/COVID-19-Public-Therapeutic-Locator/rxn6-qnx8/data>

<https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Antiviral-Therapeutics.aspx>

<https://www.scvmc.org/patients-visitors/services/covid-19-oral-antiviral/pharmacy-location-inventory>

General prescribing guidelines for oral antivirals

[How to Reserve Medications - Santa Clara Valley Medical Center - \(scvmc.org\)](#)

Requests for outpatient infusion of remdesivir or monoclonal antibody therapy can be initiated through online referral forms below:

[Healthcare provider referral form](#)

[Patient self-referral form](#)